Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AVE8062 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AVE8062 / Docetaxel | EXPERIMENTAL | AVE8062 30-minute IV, 11.5 to 42 mg/m2, followed by Docetaxel, 1-hour IV, 75 and 100 mg/m2 in 3-week cycles until disease progression or unacceptable toxicity or study discontinuation criteria |
| Name | Type | Description |
|---|---|---|
| AVE8062 | DRUG | Pharmaceutical form:Solution for infusion Route of administration: Intravenous |
| Docetaxel | DRUG | Pharmaceutical form: solution for infusion Route of administration: Intravenous |
Inclusion criteria: * Advanced neoplastic disease (i.e metastatic or locally advanced disease) for which docetaxel-based regimen therapy is indicated such as breast, non-small cell lung and prostate cancer. * ECOG performance status of 0 to 1. Exclusion criteria: * Concurrent treatment with any o...
AVE8062 is an investigational small molecule being studied for the treatment of advanced neoplastic disease, a type of cancer. It is currently in clinical development and has not been approved by regulatory authorities. The drug is being evaluated in patients with advanced solid tumors.
AVE8062 is being developed by Sanofi, a global biopharmaceutical company listed on the stock exchange under the ticker SNY. Sanofi is conducting clinical trials to evaluate the safety and efficacy of this investigational oncology drug.
AVE8062 is in Phase 1 clinical development. This early-stage trial is designed to assess the drug's safety, tolerability, and pharmacokinetics in patients with advanced solid tumors. The drug is investigational and has not yet received regulatory approval.
AVE8062 has one completed clinical trial registered under NCT01907685. This Phase 1 study, titled "Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors," enrolled 58 participants with advanced neoplastic disease.
AVE8062 is being studied in a Phase 1, open-label, uncontrolled clinical trial. The study combines AVE8062 with docetaxel in patients with advanced solid tumors. The trial is not randomized or double-blinded, and it does not use a control group or biomarker selection.